Seattle Children’s launches CureWorks, a project aimed at revolutionizing cancer treatment for kids– 6.12.2018 – GeekWire
New cancer immunotherapies could revolutionize how we treat the disease, but for many children, those treatments are far out of reach. A new collaboration between four children’s hospitals across North America is working to solve that. The collaborative, called CureWorks, is spearheaded by Seattle Children’s and will allow patients at the three other member hospitals to receive cutting-edge CAR T immunotherapy treatments. “What we hope to do through CureWorks is to, in a sense, democratize access to these very complex but potentially revolutionary cancer immunotherapies for children,” said Dr. Mike Jensen, CureWorks’ executive director and director of the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute.
I was not ready to die: How Seattle Children’s immunotherapy saved my life – 3.22.2018 – On the Pulse
Seattle Children’s doctors and researchers are leading efforts to better treat cancer in children, adolescents and young adults by boosting the immune system with T-cell immunotherapy. Patients who cannot be cured with standard therapies are benefiting from clinical trials developed at the Ben Towne Center for Childhood Cancer Research, and supported by the Strong Against Cancer initiative. One of these patients is Aaron. When he feared he might be out of treatment options, Aaron found hope at Seattle Children’s. Now, he shares his story.
Abatacept may reduce graft-versus-host disease after hematopoietic stem cell transplantation – 3.22.2018 – Healio
The addition of abatacept to standard therapy reduced the incidence of severe acute graft-versus-host disease to less than 5%, according to phase 2 study results presented at ASH Annual Meeting and Exposition. Incidence of grade 3 or grade 4 GVHD decreased from 32% to 3% among patients who underwent mismatched unrelated donor stem cell transplants for advanced malignancies and received standard prophylaxis plus abatacept in the posttransplantation setting, according to Dr. Leslie Kean, associate director of the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute.